Drug Trial Radar · NCT07874815
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,136
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Apr 29, 2029
Study completion Apr 29, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also evaluate the efficacy of ensifentrine compared with placebo in improving lung function, improving health related quality of life, and preventing severe exacerbations.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
EnsifentrineDrug
Delivered twice daily by oral inhalation via a standard jet nebulizer
PlaceboOther
Placebo matched to ensifentrine delivered twice daily by oral inhalation via a standard jet nebulizer
Standard of Care (SOC)Drug
Background treatment of LAMA/LABA/ICS or LAMA/LABA (if ICS is not appropriate) administered per product approved label delivered by oral inhalation as part of standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Adjudicated Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) ExacerbationsTime frame: Up to 52 Weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Family First Medical Research Center ( Site 4458)
Hialeah Gardens, Florida · Recruiting
Advanced Pulmonary Research Institute ( Site 4427)
Loxahatchee Groves, Florida · Recruiting
Velocity Clinical Research ( Site 4464)
Valparaiso, Indiana · Recruiting
CHEAR Center LLC ( Site 4407)
The Bronx, New York · Recruiting
Lowcountry Lung & Critical Care, PA ( Site 4413)
Charleston, South Carolina · Recruiting
M3 Wake Research, Inc. ( Site 4440)
Chattanooga, Tennessee · Recruiting
Victoria Clinical Research Group ( Site 4430)
Victoria, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.